News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biosign Technologies Inc. Appoints Dr. Scott Jenkins as CEO



6/23/2011 6:50:38 AM

Biosign Technologies Appoints Dr. Scott Jenkins as CEO

PR Newswire

-Healthcare IT executive to lead international health monitoring company-

TORONTO, June 22, 2011 /PRNewswire/ - Biosign Technologies Inc. (TSXV: BIO), a company focused on non-invasive, cloud based-health monitoring, is pleased to announce that Dr. Scott Jenkins has been appointed as Chief Executive Officer (CEO) of the company, effective July 5, 2011. Dr. Jenkins will assume this role from Biosign's acting CEO and Founder, Dr. Radu Leca.

Dr. Jenkins has extensive experience in healthcare, life sciences, medical devices and information technology business development and global sales. Most recently, Dr. Jenkins was the Vice President of Worldwide Solution Sales at DELL Healthcare and Life Sciences, where he was directly responsible for managing over 500 channel solution partners. Previously, Dr. Jenkins has held various senior positions with, Applied Biosystems, IBM Healthcare & Life Sciences, and Apple.

"The Board was searching for an individual to take Biosign to the next level on a global scale," stated Dr. David Silver, Biosign's Chairman. "We are thrilled to have attracted an individual like Scott who can combine deep scientific understanding, healthcare technology industry solutions and global sales - and has a proven track record of doing so for other global organizations."

"After using the UFIT system for several months and fully understanding its unique capabilities and broader potential for personalized medicine, I realized that my background and experience are perfectly suited to help Biosign grow and realize its full potential," stated Dr. Jenkins.

In connection with Dr. Jenkins' appointment, Biosign will be centralizing the sales and marketing operations of the company in the San Francisco bay area, while keeping the science and technology development activities in Thornhill, Ontario, under the direction of Dr. Leca, President.

Dr. Jenkins has lectured and presented papers at numerous worldwide conferences, including the Milken Institute, Best Practices in Personalized Medicine, The Galan Institute and Personalized Medicine World. Dr. Jenkins earned a B.S. Organic Chemistry, Minnesota State University and his Ph.D. in Synthetic Organic Chemistry, University of Minnesota.

About Biosign Technologies Inc

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward- looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information, please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES